welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy
study id #: NCT01645098
condition: Duchenne Muscular Dystrophy
This is an interventional study on Duchenne muscular dystrophy patients who will be receiving sedation for a muscle biopsy as part of another study.
intervention: Ketamine, Dexmedetomidine
mechanism of action: Sedation during moderately painful procedures
last updated: November 22, 2018
start date: August 2011
estimated completion: June 2013
phase of development: N/A
size / enrollment: 53
- Time to Sedation Score of 3-4 [ Time Frame: Immediately prior to incision ]
The depth of sedation was judged using the University of Michigan Sedation Scale (UMSS). The score ranges from zero, awake and alert, to four, unarousable. A score of three, deeply sedated, or more was considered to be an appropriate level of sedation for the procedure.
- Heart Rate Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Difference in heart rate from baseline to immediately following infusion of dexmedetomidine loading dose.
- Mean Arterial Pressure (MAP) Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in MAP from baseline measurement to immediately post dexmedetomidine infusion measured via blood pressure cuff.
- Oxygen Saturation Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in oxygen saturation from baseline measurement to immediately post dexmedetomidine infusion.
- EtCO2 Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in end-tidal carbon dioxide from baseline measurement to immediately post dexmedetomidine infusion.
Patients undergoing a muscle biopsy for IRB11-00203.
Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on CorticosteroidsThe purpose of the study is to assess th...
Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dy...Duchenne/Becker muscular dystrophy (DMD/...
Mother-caregivers of Children With Duchenne Muscular DystrophyThe incidence of Duchenne Muscular Dystr...
A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy (REACH-DMD)The purpose of this study is to evaluate...
A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to determin...
Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 SkippingPreU7-53 is a natural history study. The...
Systemic Gene Delivery Clinical Trial for Duchenne Muscular DystrophyThe proposed clinical trial is a single-...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular DystrophyRecent increases in the number and bread...
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...
Duke Children’s Seeing Results From Duchenne Muscular Dystrophy Trialhttps://www.youtube.com/watch?v=aLfES8ZH...